{
    "Trade/Device Name(s)": [
        "ACL TOP 970 CL",
        "HemosIL CL Anti-Cardiolipin IgM",
        "HemosIL CL Anti-B2 Glycoprotein-I IgM"
    ],
    "Submitter Information": "Instrumentation Laboratory Co.",
    "510(k) Number": "K221359",
    "Predicate Device Reference 510(k) Number(s)": [
        "K083518",
        "K092181",
        "K091556"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "JPA",
        "MID",
        "MSV"
    ],
    "Summary Letter Date": "September 29, 2023",
    "Summary Letter Received Date": "May 11, 2022",
    "Submission Date": "May 10, 2022",
    "Regulation Number(s)": [
        "21 CFR 864.5425",
        "21 CFR 866.5660"
    ],
    "Regulation Name(s)": [
        "Multipurpose system for in vitro coagulation studies",
        "System, Test, Anti-cardiolipin Immunological",
        "System, Test, Antibodies, \u03b22 - Glycoprotein I (\u03b22 - Gpi)"
    ],
    "Analyte Class(es)": [
        "hematology",
        "immunology",
        "coagulation"
    ],
    "Analyte(s)": [
        "Anti-cardiolipin IgM antibodies",
        "Anti-B2 Glycoprotein-I IgM antibodies"
    ],
    "Specimen Type(s)": [
        "Human citrated plasma"
    ],
    "Specimen Container(s)": [
        "3.2% citrated plasma tube",
        "3.8% citrated plasma tube"
    ],
    "Instrument(s)/Platform(s)": [
        "ACL TOP 970 CL"
    ],
    "Method(s)/Technology(ies)": [
        "Chemiluminescent immunoassay"
    ],
    "Methodologies": [
        "Two-step chemiluminescent immunoassay"
    ],
    "Submission Type(s)": [
        "Analyzer",
        "Assay"
    ],
    "Document Summary": "FDA 510(k) summary for ACL TOP 970 CL analyzer and HemosIL CL Anti-Cardiolipin IgM and Anti-B2 Glycoprotein-I IgM chemiluminescent immunoassays for detection of antiphospholipid antibodies.",
    "Indications for Use Summary": "ACL TOP 970 CL: Fully automated analyzer for in vitro diagnostic use in clinical laboratories. HemosIL CL Anti-Cardiolipin IgM and Anti-B2 Glycoprotein-I IgM: Semi-quantitative detection of respective IgM antibodies in human citrated plasma, aiding in diagnosis of Antiphospholipid Syndrome (APS) for adult patients, used in conjunction with other findings.",
    "fda_folder": "Hematology"
}